Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.

Abstract

Atopic dermatitis (AD) is a common diagnosis seen in both children and adults, and it is often the first manifestation of atopic disease. Research has shown a strong correlation between serum IgE levels, the severity of atopic dermatitis, and co-existing asthma and/or allergic rhinitis. Omalizumab (Xolair, East Hanover, NJ; Genentech, South San Francisco, CA) is a monoclonal antibody to human IgE and is currently Food and Drug Administration (FDA) approved for the treatment of asthma. We present 3 patients with severe, treatment resistant atopic dermatitis whose cutaneous symptoms significantly improved by treatment with omalizumab.

• Authors: David Amrol
• Journal: Southern medical journal (South Med J) Vol. 103 Issue 6 Pg. 554-8 (Jun 2010) ISSN: 1541-8243 [Electronic] United States
• PMID: 20710140 (Publication Type: Journal Article)

Chemical References

• Adrenal Cortex Hormones
• Anti-Allergic Agents
• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Omalizumab
• Immunoglobulin E

Topics

• Administration, Topical
• Adrenal Cortex Hormones (therapeutic use)
• Adult
• Anti-Allergic Agents (therapeutic use)
• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Child
• Dermatitis, Atopic (drug therapy, immunology)
• Drug Therapy, Combination
• Female
• Humans
• Immunoglobulin E (immunology)
• Male
• Omalizumab